Abstract:Amyotrophic lateral sclerosis (ALS) is a progressive neurodegenerative disorder that leads to the degeneration of motor neurons and the weakening of muscles. Despite extensive research efforts, there is currently no cure for ALS and existing treatments only address its symptoms. To address this unmet medical need, genome editing technologies, such as CRISPR-Cas9, have emerged as a promising solution for the development of new treatments for ALS. Studies have shown that CRISPR-Cas9-guided RNAs have the potential to provide accurate and effective silencing in the genetic disease of ALS. Results have demonstrated a 67% on-target score and a 98% off-target score with GC content within the range of 40-60%. This is further validated by the correlation between the gRNA's structural accuracy and the minimum free energy. The use of CRISPR-Cas9 provides a unique opportunity to target this disease at the molecular level, offering hope for the development of a more effective treatment. In silico and computational therapeutic approaches for ALS suggest that the CRISPR-Cas9 protein holds promise as a future treatment candidate. The CRISPR mechanism and the specificity of gRNA provide a novel therapeutic approach for this genetic disease, offering new hope to those affected by ALS. This study highlights the potential of CRISPR-Cas9 as a promising solution for the development of new treatments for ALS. Further research is required to validate these findings in preclinical and clinical trials and to establish the safety and efficacy of this approach in the treatment of ALS.

CRISPR/Cas9: implication for modeling and therapy of amyotrophic lateral sclerosis

CRISPR/Cas9-Mediated Gene Correction to Understand ALS

CRISPR/Cas9 Technology as an Emerging Tool for Targeting Amyotrophic Lateral Sclerosis (ALS)

CRISPR-Cas9 guided rna based model for the treatment of Amyotrophic Lateral Sclerosis: A progressive neurodegenerative disorder

Mouse models of ALS: Past, present and future

From Mouse Models to Human Disease: An Approach for Amyotrophic Lateral Sclerosis

Promising animal models for amyotrophic lateral sclerosis drug discovery: a comprehensive update

Invertebrate genetic models of amyotrophic lateral sclerosis

In Vitro Models of Amyotrophic Lateral Sclerosis

In vivo genome editing improves motor function and extends survival in a mouse model of ALS

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases

CRISPR/Cas9: Implications for Modeling and Therapy of Neurodegenerative Diseases.

The usage and advantages of several common amyotrophic lateral sclerosis animal models

Efficacy and long-term safety of CRISPR/Cas9 genome editing in the SOD1-linked mouse models of ALS

New developments in pre-clinical models of ALS to guide translation

Modeling cell-autonomous motor neuron phenotypes in ALS using iPSCs

Murine experimental models of amyotrophic lateral sclerosis: an update

Amyotrophic lateral sclerosis: translating genetic discoveries into therapies

Amyotrophic Lateral Sclerosis Mechanism: Insights from the Caenorhabditis elegans Models

CRISPR/Cas9-mediated targeted gene correction in amyotrophic lateral sclerosis patient iPSCs

Recent progress of the genetics of amyotrophic lateral sclerosis and challenges of gene therapy